C
hronic liver diseases and their complications including liver cirrhosis are major public health concerns worldwide, due to the associated significant morbidity and mortality.
(1) Acute kidney injury (AKI) in hepatorenal syndrome (HRS) is a potentially lethal complication of liver failure that is characterized by a rapid decline in renal function in cirrhotic patients. Although the definition and diagnostic criteria of type-1 and type-2 HRS and AKI-HRS are in constant flux, (2) it is now generally accepted that a diagnosis of HRS can be made when renal dysfunction develops in patients with advanced cirrhosis and ascites. (3) HRS is present in 20-50% of hospitalized cirrhotic patients (4) and is considered a serious complication often precipitated by bleeding, bacterial/viral infections or dehydration. AKI in HRS has a poor prognosis and is an important predictor of short-term mortality in patients with cirrhosis (5) and their survival and outcome when they undergo liver transplantation. (6) Our understanding of the pathogenesis of kidney dysfunction in advanced liver failure is limited. There are no perfect animal models for HRS, which likely reflects the difficulty in inducing advanced liver failure in experimental animals without the use of poisonous hepatotoxins (e.g., carbon tetrachloride, acetaminophen, D-galactosamine, thioacetamide, and so on) which may damage the kidneys directly. Nonetheless, clinical observations point to the critical pathogenic role of severe vasodilation in the splanchnic vasculature seen in decompensated liver failure, which, in turn, induces compensatory vasoconstriction, leading to renal circulatory derangement. (7) Other theories focus on the role of aggravated systemic inflammation and bacterial translocation seen in decompensated cirrhosis, (8) and on the importance of cardiac (9) and adrenal insufficiency. (10) A separate entity described in patients suffering from biliary obstruction is cholemic nephropathy, which results from the toxic effects of bile acids and bilirubin casts on the tubular apparatus. (11) (12) (13) All of the aforementioned extrarenal factors likely contribute to the development of kidney injury, while intrarenal mechanisms that may lead to tubular cell death in HRS have not yet been identified.
Our lack of understanding of its pathogenesis aside, AKI-HRS is probably one of the most challenging complications of liver cirrhosis to treat. Its preferred treatment is liver transplantation, but many patients unfortunately die before transplantation due to organ shortage and the short survival associated with AKI-HRS. Supportive treatment aims to improve renal function before transplantation, as patients with AKI-HRS receiving liver transplantation have greater mortality than those with other diagnoses. (14) Current therapeutic options are limited and usually target extrarenal triggers of HRS, for example by trying to correct the hypovolemia and splanchnic vasodilation through the use of volume expanders and somatostatin and vasopressin analogues.
Therefore, we aimed to develop and characterize a pathologically relevant mouse model of AKI-HRS without the use of hepatotoxins and to study intrarenal mechanisms that might contribute to the development of tubular injury. We report that bile-duct-ligated mice develop tubular injury, tubulointerstitial nephritis and fibrosis that closely resemble the histological features seen in patients suffering from AKI-HRS. In this model, disruption of renal arginine metabolism contributes to the impairment of the renal microcirculation and tubular injury. Genetic deletion of arginase-2 (ARG2) partially protects against bile duct ligation (BDL)-induced HRS, which implicates an intrarenal disease-specific pharmacological target for alleviating kidney injury and delaying its progression to HRS.
Materials and Methods

aNIMalS
All animal protocols conformed to the National Institutes of Health (NIH) guidelines and were approved by the Institutional Animal Care and Use Committee of the National Institute on Alcohol Abuse and Alcoholism (Bethesda, MD). We obtained 10 to
15-week-old male C57BL/6J or Arg2 −/− mice from the Jackson Laboratory (Bar Harbor, ME). Wild-type (WT) and Arg2 −/− mice were used in the study.
BIle DUCt-lIgatIoN MoDel
BDL surgery was performed as described in detail in the Supporting Information Methods. (15) 
INDICatorS oF KIDNey aND lIVer INJUry
Serum levels of alanine aminotransferase (ALT), alkaline phosphatase (ALKP), blood urea nitrogen (BUN), urinary urea nitrogen, creatinine, and ammonia were measured using a clinical chemistry analyzerIdexx VetTest 8008 (Idexx Laboratories, Westbrook, ME). Urinary creatinine, urinary sodium were measured with colorimetric kits from Biovision Inc. (Milpitas, CA).
Serum levels of the tubular injury markers, kidney injury molecule-1 (KIM1), and osteopontin were measured by commercially available ELISA kits (Cat#MKM100, MOST00, R&D Systems, Minneapolis, MN).
arterIal aND MICroVaSCUlar FloW MeaSUreMeNtS
Blood flow in the renal artery was measured using a flow probe (Transonic Systems Inc. Ithaca, NY); renal microcirculation was assessed by the laser speckle contrast approach as described in the Supporting Information.
Cyclic guanosine monophosphate (cGMP), arginase and eNOS activity measurements are described in the supplemental methods. Reverse Transcription and Real-Time PCR analyses were performed as previously described. (15) Primer sequences are provided in Supporting Table S1 .
Histology, Immunohistochemistry, Transmission Electron Microscopy were performed as described in the Supporting Information. (15) 
DeterMINatIoN oF SerUM Free aMINo aCID CoNteNt
Free amino acids in serum were measured by tandem mass spectrometry (LC-MS/MS) as described in the Supporting Information.
WeSterN BlotS
The details of Western blot detection of renal ARG1, ARG2, argininosuccinate synthase 1 (ASS1) and HIF1-α proteins are provided in the Supporting Information.
aMMoNIa aND eNDotoXIN eXpoSUre oF CellS
Culture and ammonia exposure of human renal proximal tubular epithelial cells (RPTEC) and human umbilical vein endothelial cells (HUVEC) are described in the Supporting Information.
StatIStICal aNalySIS
Values are represented as mean ± SEM. Statistical analysis of the data was performed by unpaired T-test or one-way analysis of variance (ANOVA) followed by Tukey's post-hoc test for multiple comparisons, as appropriate. The analysis was conducted using GraphPad-Prism6 software. P <0.05 was considered statistically significant.
Results
BIle DUCt-lIgatIoN leaDS to HepatIC INJUry
We first characterized time-dependent changes of body weight and liver injury in the mouse BDL model ( Fig. 1 and Supporting Fig. S1 ). There was an apparent change in hepatic tissue architecture as early as 7 days after BDL characterized by pronounced biliary inflammation with scattered small necrotic foci and fibrosis predominantly localized around inflamed bile ducts. By day 14 post-ligation, fibrosis spread to the liver parenchyma (Fig. 1A) . The rapid onset of liver injury was paralleled by the increased expression of markers of fibrotic remodeling (Tgfb1, Col1a1, Col3a1) and inflammation (Tnf, Ccl3, Cxcl2) (Fig. 1B) . Tissue injury was reflected by elevations of the serum alanine aminotransferase (ALT-marker of hepatocyte necrosis), and alkaline phosphatase (ALKP-marker of biliary injury) (Fig. 1C) . Serum markers of renal dysfunction (BUN and creatinine) were also increased (Fig. 1D ) at 7 and/ or 14 days after BDL, which prompted us to investigate the renal consequences of liver injury and to identify possible intrarenal causes for the kidney damage. 
BIle DUCt-lIgatIoN leaDS to progreSSIVe tUBUlar INJUry IN tHe KIDNey
We observed progressive tubular damage in the cortical parts of the kidneys after BDL, associated with increased kidney/body weight ratio ( Fig. 2A-C) . Tubular injury was characterized by the markedly elevated circulating levels of kidney injury molecule 1 (KIM-1) and osteopontin, known biomarkers of acute kidney injury (Fig. 2D ). Histological analyses provided further evidence for tubular injury in the form of dilated tubules containing protein casts at day 7 post-ligation ( Fig. 2A) . By day 14, massive tubular dilation with extensive cast formation became visible. The injured and dilated tubuli were strongly expressing lipocalin 2, a widely used biomarker for acute kidney injury. In addition, renal interstitial fibrosis that was not evident at day 7 became visible by day 14 ( Fig. 2A) . Transmission electron microscopy of tubular epithelial cells from sham operated mice showed normal mitochondrial morphology and distribution. In BDL mice sacrificed on postoperative day 7, proximal tubular cells had maintained brush border, and mitochondria of various size and shape were present (megamitochondria formation could be seen in some tubules, most likely because of altered microcirculation and progressively ischemic microenvironment). On postoperative day 14, when proximal tubules were greatly injured and dilated, the brush border was diminished/lost. Mitochondria were significantly decreased in number, due to an increase in autophagy. Those that remained were largely detectable within autophagolysosomes (Fig. 2B) . Furthermore, the expression of markers of tubular injury (Havcr1 -KIM-1, Lcn2-lipocalin-2, Fabp1-fatty acid binding protein 1, Vim -vimentin) was robustly increased (Fig. 2E , left panel) in renal cortices from BDL mice. In contrast, there was a profound reduction in the expression of markers of proximal tubular cell function (megalin [Lrp2] and cubilin [Cubn] --both involved in protein reabsorption; sodium/glucose cotransporter 2/(Slc5a2) -known as SGLT2 -involved in glucose reabsorption; and Slc34a1 -the proximal tubular specific sodium/phosphate cotransporter) (Fig. 2E, right  panel) . We also found increased expression of several pro-inflammatory cytokines (Il1b, Il6, Tnfa, Ccl2, Ccl3, and Cxcl2) (Fig. 2F, left panel) and pro-fibrotic genes (Tgfb1, Col1a1, and Col3a1) (Fig. 2F, right  panel) .
BIle DUCt-lIgatIoN leaDS to MICroVaSCUlar INJUry IN tHe KIDNey
Chronic interstitial and tubular cell hypoxia (16) as a result of microvascular dysfunction is a major trigger of tubular cell death, and is associated with the development of interstitial fibrosis. (17, 18) Therefore, we looked for changes in peritubular endothelial cells, and found that the fenestrations that were evident in the sham operated mice significantly diminished in BDL mice, in addition the endothelium became focally detached (Fig. 3A) . We measured the blood flow in the renal artery using an ultrasonic probe as well as renal microvascular function, quantified by laser speckle contrast analysis in BDL and control mice. Blood flow through the renal artery was not significantly changed (P = 0.35) 14 days after BDL (0.33±0.02 mL/minute) as compared to sham operated mice (0.37±0.04 mL/minute). In contrast, there was a dramatic time-dependent reduction in microvascular flow in the kidneys of BDL mice, suggesting the involvement of hypoxia in the development of the kidney pathology seen (Fig.  3 B,C) . Parallel to the decreased microcirculation, we detected a significantly increased expression of hypoxia-inducible factor 1-alpha (Hif1a), the gene encoding the transcription factor hypoxia-inducible factor 1-α in the kidneys of BDL mice (Fig. 3D) . In contrast, at the protein level we observed decreased phosphorylation of HIF1α (Fig. 3E ) in the kidney of BDL mice that likely results from chronic hypoxia. When dephosphorylated, HIF1α is unable to bind HIF1β, and thereby to enter the nucleus and induce the expression of hypoxia responsive genes. (19, 20) Accordingly, gene expression of angiogenic factors such as Vegfa (vascular endothelial growth factor A) and Angpt1 (angiopoietin 1) decreased significantly by day 14 following BDL (Fig. 3D) . In addition, the VEGF-A receptor vascular endothelial growth factor receptor 2 ([Kdr] Kinase insert domain receptor) and the angiopoietin 1 receptor Tie1 (Tyrosine kinase with immunoglobulin-like and EGFlike domains 1) were also expressed at significantly lower levels in the kidney of BDL compared to control mice (Fig. 3D) . To further test if vascular inflammation contributes to microcirculatory dysfunction, we assessed the expression of vascular adhesion molecules. The renal expression of platelet endothelial cell adhesion molecule 1 (Pecam1) and Cdh5 (VE-cadherin) remained unchanged, whereas the expression of vascular cell adhesion molecule 1 (Vcam1), intercellular adhesion molecule 1 (Icam1), E-selectin (Sele), and P-selectin (Selp) increased (Fig. 3F) , suggesting increased renal vascular inflammation and consequent dysfunction.
DISSoCIatIoN oF reNal argININe MetaBolISM IN BIleDUCt-lIgateD MICe
The kidney has a central role in systemic arginine metabolism, a process that is closely coupled to ammonia detoxification (also known as the urea cycle [ Fig. 4A]) . Renal arginine synthesis is a major endogenous source of arginine, and the urea cycle enzymes responsible for arginine synthesis, argininosuccinate synthase 1 (ASS1) and argininosuccinate lyase (ASL) are highly and almost exclusively expressed in kidney. (21) In healthy humans, the liver controls ammonia metabolism via the urea cycle, while the kidney is responsible for urinary ammonium ion excretion (by breaking down glutamine via the kidney specific glutaminase). (22) Liver failure is often associated with disturbed ammonia homeostasis and the consequent development of hyperammonemia. Serum ammonia levels were markedly increased in BDL mice (Fig. 4B) . It is known that the interorgan trafficking of ammonium is altered in hepatic disease, (23) however, the extent to which renal urea cycle and arginine metabolism are modified by hyperammonemia is not known. We found decreased expression of glutamine synthase (Glul) and glutamate dehydrogenase (Glud) both in the liver and kidney of BDL mice, suggesting impaired ammonia detoxification by these two pathways (Fig. 4C) . The liver showed decreased expression of the critical urea cycle enzyme ornithine transcarbamylase (Otc), while there was a slight induction of arginase-1 (Arg1), and a marked induction of arginase-2 (Arg2) expression (Fig. 4C, upper panel) . In contrast, the kidney did not express the urea cycle enzymes carbamoyl phosphate synthetase 1 (Cps1) and ornithine transcarbamylase (Otc). However, the expression of argininosuccinate synthase 1 (Ass1) and argininosuccinate lyase (Asl) was markedly reduced (Fig. 4C lower panel, D) , both being involved in de novo arginine synthesis. Surprisingly, the expression of both arginase isoforms markedly increased both at the mRNA (Fig. 4C, lower panel) and protein levels (Fig. 4E) , suggesting decreased de novo synthesis and enhanced renal breakdown of arginine. The cell type-specific expression of the arginase isoforms was analyzed by immunohistochemistry (Fig. 4F) . Arginase-1 was localized around some damaged and dilated tubules 14 days after BDL (Fig. 4F , upper panels), while arginase-2 displayed a diffuse, tubularspecific staining that progressively increased after BDL (Fig. 4F, lower panels) .
To see if changes in the expression of these key urea cycle enzymes result in altered levels of free amino acids in the serum, we measured amino acids (see Supporting  Table S2 ) and amino acid intermediates of arginine metabolism by mass spectrometry, as illustrated in Fig. 5 . We detected a marked drop in serum arginine levels (Fig. 5A ) that paralleled significant increases in ornithine and citrulline levels, indicating increased breakdown of arginine by both arginases and nitric oxide synthases (NOS). Serum aspartate and glutamate levels were not altered; however, we found a slight but significant increase in serum glutamine levels, the latter likely being a result of increased skeletal muscle glutamine synthesis (Fig. 4A, Supporting Fig. S2 ), as an alternative ammonia detoxification pathway. (24, 25) There were no significant changes in the expression of NOS isoforms in the kidney (Fig. 5B) , whereas inducible NOS (Nos2) was robustly increased in the liver of BDL mice, in line with findings by others. (26) These changes were paralleled by the increased enzyme activity of arginase, and a marked drop in the activity of endothelial NOS (Fig. 5, panels C,D) . Cyclic guanosine monophosphate (cGMP), a marker of NOS activity, decreased in the kidneys of BDL mice (Fig. 5E) , suggesting impaired NO production that is likely a result of the depleted arginine pool. We noted that 3-Nitrotyrosine (3-NT) formation, a marker of peroxynitrite generation or more broadly nitrative stress, (27) was also increased around the dilated tubules in BDL mice (Fig. 5F ), consistent with decreased NO availability and enhanced protein oxidation/nitration.
geNetIC DeletIoN oF argINaSe-2 atteNUateS tHe DeVelopMeNt oF reNal INJUry IN BDl MICe
We further investigated the role of disturbed arginine metabolism in renal injury by using Arg2 −/− and corresponding wild type (WT) mice. Despite the similar levels of liver injury (Fig. 6A) , inflammatory cytokines, fibrotic markers (data not shown) and serum ALT (Fig. 6B ) in the two strains, blood urea nitrogen and creatinine were significantly lower in the Arg2-/-mice (Fig. 6B) , suggesting better preservation of renal function. Consistently, tubular architecture was also better preserved with less tubulointerstitial fibrosis in Arg2 −/− compared to WT mice (Fig. 6C) . Furthermore, BDL resulted in a smaller reduction in cortical microcirculation in Arg2 −/− than in WT mice (Fig. 6D,E) . At the same time, the significant drop in liver microcirculation induced by BDL was similar in Arg2 −/− and WT mice (Supporting Fig. S3A,B) .
HyperaMMoNeMIa trIggerS tHe UpregUlatIoN oF argINaSe-2 aND MarKerS oF tUBUlar INJUry IN HUMaN proXIMal tUBUlar epItHelIal CellS
In further in vitro experiments we tested whether ammonia per se can alter the expression of arginases and tubular-injury markers. RPTEC treated with ammonia showed a concentration-dependent upregulation of arginase-2, while arginase-1 was not detectable in these cells (Fig. 7A) . Arginase-2 expression remained unchanged in the presence of 100 ng/mL endotoxin, suggesting inflammation-independent induction of arginase-2 by hyperammonemia. Furthermore, a high concentration of ammonia significantly reduced the expression of proximal tubular-specific claudin-2 (Cldn2) (28) and Lrp2, and increased Lcn2 expression (Fig. 7C) . However, the expression of arginase-2 was unaffected by any of the treatments in human umbilical vein endothelial cells (HUVEC) (Fig. 7B) .
We also tested the effects of the three most common bile acids detectable in the serum of BDL animals at pmol/mL amounts (12) on arginase-2 expression in RPTEC. Only chenodeoxycholic acid at the highest 100 uM concentration, but not cholic acid and taurocholic acid at 1 and 100 uM concentrations, increased the expression of Arg2 (Supporting Fig. S4 ). 
Discussion
Here we propose a mechanism by which kidney injury develops in HRS, based on findings in BDL mice. In this model, pathological changes in the kidney closely resemble the histopathological findings in the kidneys of patients with HRS. Our key finding is that the disruption of renal arginine metabolism plays a significant role in the development of renal pathology in HRS. We show that (1) BDL leads to progressive renal tubular injury that is likely related to impaired microvascular function as a consequence of decreased NO availability; (2) BDL-induced liver failure results in hyperammonemia, and a shift in the expression of ammonia detoxifying enzymes both in the liver and kidney, leading to decreased de novo production as well as increased breakdown of arginine in the kidneys; (3) genetic deletion of arginase-2 mitigates the development of kidney injury, and protects renal microcirculation in BDL mice; (4) arginase-2 is selectively upregulated in human proximal tubular cells by hyperammonemia.
Rapid deterioration of renal function due to AKI in end-stage liver disease is a life-threatening complication, which often develops on the background of HRS. (29) Concomitant infections, extreme jaundice and intrahepatic cholestasis contribute to the acute decompensation of cirrhosis and consequently to the development of kidney injury. (3) In BDL mice, all these factors that contribute to decompensation are present and rapidly progressing, (30) which makes this a suitable model of kidney injury associated with cholestatic liver failure. (12) Hyperammonemia is another common feature of parenchymal liver failure, and is closely linked to impaired central neural function, known as hepatic encephalopathy. Hyperammonemia has also been recently recognized as a contributing factor in the development of complications of advanced liver cirrhosis. Hyperammonemia leads to activation of myostatin via nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and thereby promoting sarcopenia, (31) while the normalization of ammonia levels helps to restore skeletal muscle mass and function. (32) In elegant studies, Jalan et al. described how hyperammonemia leads to activation of hepatic stellate cells in vitro and promotes cirrhosis in vivo by triggering free radical production and endoplasmic reticulum stress in hepatic stellate cells. (33) The same group showed that ammonia per se is capable to negatively influencing neutrophil phagocytic function, thus increasing the susceptibility to infections in liver failure. (34) However, a potential direct effect of hyperammonemia on tubular epithelium has not yet been explored. We hypothesized that hyperammonemia might also contribute to renal pathology seen in bile duct-ligated mice. The central role of the kidneys in de novo arginine synthesis and the close link of this biosynthetic pathway with ammonia detoxifying enzymes (Fig. 4A ) led us to investigate the renal expression of urea cycle enzymes, and to measure serum levels of amino acids as markers of systemic arginine homeostasis. Or results clearly indicate that BDL mice are in a systemic arginine-deficient state as a result of disturbed renal arginine production and increased arginine breakdown by arginase-2. The human body is not able to produce sufficient amounts of arginine, especially when there is increased arginine need, making it a semi-essential amino acid, which is also an important substrate for NO synthases. Sepsis and other pro-inflammatory conditions are associated with arginine deficiency, (35) which results in impaired function of eNOS, (27) a likely contributor to poor outcomes in septic patients. (27, 36) During proinflammatory conditions, NO synthases and arginases are both induced by specific cytokines. Arginase activity (mainly as a result of arginase-1 upregulation) is triggered by Th2 cytokines, such as IL-4, IL-10 and IL-13, while NO synthase expression is triggered by TLR4 activation and by Th1 and Th17 cytokines. In theory, decreased arginine availability in pro-inflammatory states might function as a protective mechanism to counteract inducible NO synthase activity and to decrease excessive and damaging NO production. However, this might impair inflammation resolving processes by T cells and macrophages, (37) (38) (39) and may also impair microvascular functions by decreasing eNOS activity/function. (40) Indeed, in the present experiments arginine pool depletion was associated with impaired renal microcirculation accompanied by a pro-inflammatory state both in the liver and kidneys. The impaired renal microcirculation in BDL was also accompanied my markedly decreased eNOS activity in the kidneys. Notably, under pro-inflammatory conditions NO synthases may also be uncoupled and produce superoxide rather than NO, which fuels oxidative and nitrative stress promoting endothelial and parenchymal injury. (27) We identified arginase-2 in the kidneys as a major cause of arginine depletion. Global genetic deletion of arginase-2 was associated with better preserved renal architecture, better kidney functions, and maintained renal microvascular flow. These results are in line with published data showing preserved renal function and better microvascular flow in diabetic arginase-2 knockout mice, as well as in diabetic mice treated with the non-selective arginase inhibitor S-(2-boronoethyl)-Lcysteine. (41) The beneficial effect of arginase inhibition on microvascular flow in persons with diabetes has also been recently documented in small clinical studies. (42) It would be intriguing to test whether pharmacological arginase-2 inhibition could attenuate kidney injury in HRS. Although several potent arginase inhibitors have recently been developed, none of them are specific for individual isoforms. (40) This limits their potential value in the treatment of liver failure, considering the crucial role of arginase-1 in hepatic ammonia detoxification. (43) We also show that ammonia can upregulate arginase-2 in human proximal tubular epithelial cells, with concomitant induction of tubular injury markers and a reduction in markers of tubular function. Thus, ammonia in concert with multiple other potential factors (inflammation, oxidative/nitrative stress, bile acids) may contribute to arginine deficiency and decreased eNOS activity, promoting microcirculatory dysfunction/injury, tissue hypoxia, and tubular damage accompanied by inflammation.
Collectively, our results highlight the importance of interorgan alterations in arginine metabolism in the development of renal injury in HRS and suggest that BDL in mice is a translational model of HRS.
reFereNCeS
